showed a trendp = 0.087
A recent clinical trial comparing voriconazole monotherapy to voriconazole and anidulafungin combination therapy for primary therapy of adults with IA showed a trend toward lower mortality with combination therapy (19.3% vs. 27.5% at 6 weeks; p = 0.087) but was underpowered for this primary endpoint [ 163 ].